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Abstract: Rosacea is a chronic inflammatory skin disease mainly affecting the facial skin. Our aim
was to determine the appearance of pro- and anti- inflammatory cytokines in rosacea-affected facial
tissue. Materials and Methods: Rosacea tissue were obtained from eight patients (aged 35 to 50 years).
The control group (CG) included four facial skin samples (49 to 70 years). Routine staining and
immunohistochemistry for IL-1, IL-10, LL-37, HBD-2, and HBD-4 proceeded. Results: Inflammation
was observed in all the rosacea samples. A statistically significant difference was seen between
epithelial HBD-2 positive cells in comparison to the control. There was a strong positive correlation
between HBD-4 in the epithelium and HBD-4 in the connective tissue, IL-10 in the epithelium
and IL-1 in the connective tissue, and IL-1 in the epithelium and IL-10 in the connective tissue.
Conclusion: Increased levels of IL-10 and decreased levels of IL-1 show the balance between anti-
and pro-inflammatory tissue responses. A significant amount of HBD-2 in the epithelium proves its
important role in the local immune response of rosacea-affected tissue. The last effect seems to be
intensified by the elevated level of LL-37 in the epithelium.
Keywords: inflammatory mediators; facial skin; rosacea; immune response
1. Introduction
Rosacea is a common chronic inflammatory disease affecting the facial skin, with an estimated
geographic prevalence variation from 1%–22% [1,2]. Four rosacea subtypes have been recognized,
with the most commonly observed features being transient and persistent facial flushing, telangiectasia,
inflammatory papules and pustules, and the hyperplasia of the connective tissue [3].
Although rosacea etiology and pathophysiology are poorly understood, a wide spectrum of trigger
factors of rosacea, such as physical (UV, temperature), biological (microbiota, food), and endogenous
(genetic, stress) stimuli [4], takes place in the manifestation of the clinical features of rosacea and
complicates the understanding of the etiology of the disease. Recent findings indicate that trigger
factors stimulate the development of innate and adaptive immune system dysregulation that can lead
to rosacea initiation and aggravation and also lead to a release of various mediators from keratinocytes,
endothelial cells, mast cells, macrophages, and T helper type 1 and Th17 cells [5]. These mediators cause
the unusually long-term relapsing inflammatory reaction in the facial skin. Therefore, pro-inflammatory
and anti-inflammatory mediators play the main role in the development of rosacea.
Immunological reactions in rosacea-affected tissues involve the secretion of some inflammatory
mediators, including IL-1, IL-10, defensin-2, defensin-4, and cathelicidin (LL-37). Interleukin-1 (IL-1)
is a pleiotropic cytokine and the primary mediator of cutaneous inflammation; that is why the
deregulation of the IL-1 system has been suggested to play one of the main roles in inflammatory skin
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diseases [6,7]. All the biological effects of IL-1 are mediated by two IL-1 receptor ligands, IL-1α and
IL-1β [6]. Keratinocytes produce IL-1α, which is associated with mechanisms of microbial invasion,
inflammation, immunological reactions, and tissue injury in the skin [8,9]. Trigger factor-induced
IL-1α production in the epithelium activates a chain of sequential reactions associated with epidermal
steam cell proliferation stimulated by the IL-1α-dependent increased activity of dermal fibroblasts [10].
IL-1β is primarily produced by monocytes and macrophages, but a limited amount is also produced
by human keratinocytes in inflammatory conditions [7]. Recent studies show that distinct cytokines
(for example, IL-1β) can also trigger beta-defensin expression [11].
Interleukin-10 (IL-10) is a key player as an anti-inflammatory cytokine and it is a negative regulator
of immune responses. Monocytes, regulatory T lymphocytes, and B cells, which have an important
place in immune response, are the major source of IL-10 in human subjects [12]. Relevant studies
have indicated that IL-10 inhibits the phase-specific infiltration of neutrophils and macrophages and
cytokine overexpression in the inflammatory response of cutaneous wound healing [13]. The suppressor
properties of IL-10 are expressed as a reduction in the activity of several inflammatory components
and a wide range of cells, including CD4+ and CD8+ T cells, B cells, antigen-presenting cells (APCs),
and natural killer (NK) cells [14].
Human β-defensins 2 encoded by the DEFB4 gene are small cationic antimicrobial polypeptides
of innate immune system which can act as a barrier against the majority of pathogens [15,16].
These antimicrobial polypeptides are highly expressed at the surface of epithelial barriers, but their
expression can also be induced in immune cells [17]. HBD-2 is the first human defence that is produced
following the stimulation of epithelial cells by different pathogen-associated molecular patterns, such as
bacterial lipoprotein, LPS, and other TLR agonists and by distinct cytokines such as IFN-γ and IL-1β
that can also promote beta-defensin expression [11,18]. Evidence that HBD-2 stimulates keratinocyte
migration and proliferation, stimulates cytokine or chemokine production, and initiates the process of
tissue repair expands their role as immune regulators and enhances the importance of these mediators
in human innate immunity [19]. Human beta defensin 2 plays one of the main roles in the development
of rosacea according to its wide spectrum of activating factors and effects on keratinocytes.
HBD-4 are small, multifunctional cationic peptides which are expressed in certain epithelia and
neutrophils [20,21]. HBD-4 reportedly has antimicrobial activity, especially against Pseudomonas
aeruginosa, and is not normally expressed in unaffected skin [22]. Furthermore, the gene expression of
HBD-4 in keratinocytes is upregulated by TNF-α, IL-1β, Ca2+, and phorbol 12-myristate 13-acetate
(PMA) [23].
LL-37, the sole human cathelicidin, is an antimicrobial peptide that is able to act as an anti- and
pro-inflammatory factor [24,25]. Cathelicidins are able to differentiate normal cells, abnormal cells,
and pathogens; they directly and selectively destroy the membranes of various microbes and cancer
cells, but at the same time normal cells are not damaged [25]. LL-37 are produced by many different
cells, such as macrophages, neutrophils, and keratinocytes [26]. Mast cells are one of the primary
sources of cathelicidin LL-37, and their (mast cells) number is increased in the dermis of rosacea
patients [27]. The activation of CAMP gene and secretion of cathelicidin mRNA in keratinocytes is
strongly induced by the activation of the vitamin D pathway (UV as a trigger factor), and this could
explain why rosacea occurs mainly in the facial skin [28]. Overall, the higher cathelicidin expression
in rosacea supports the hypothesis that an abnormal inflammatory response of the innate immune
system has an important place in the pathophysiology of rosacea.
The aim of this work was to compare different pro- and anti-inflammatory mediator activities in
rosacea-affected facial skin and healthy tissue.
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2. Materials and Methods
2.1. Material Characteristics of Subjects
This study was approved by the Ethics Committee for Clinical Research of Medicine and
Pharmaceutical Products at Pauls Stradins Clinical University Hospital Development Foundation in
Latvia (Nr.190107 – 1L/z). All of the patients gave their informed consent to participate in the study after
the nature of the study had been fully explained. Rosacea patients underwent a biopsy of the nasolabial
region of the face under local anesthesia. A special “punch” method was used for skin biopsies.
The pieces of biopsy tissue were approximately 2–3 mm2 (square millimeters), containing epidermis
and dermis, including cells of these layers. The study was conducted at the Institute of Anatomy and
Anthropology, Latvia. The facial skin material was obtained from 8 rosacea patients, with 3 males in
the age from 32–36 years and 5 females in the age from 35 to 50 years. Four control specimens were
obtained from patients with variable age (from 49 to 70) and gender (2 males, 2 females) during facial
plastic surgery. Tissues were not associated with inflammation, rosacea, or any other pathology.
2.2. Immunohistochemical Analysis
The tissue specimens were fixed in a mixture of 2% formaldehyde and 0.2% picric acid in 0.1 M
phosphate buffer (pH 7.2). Afterwards, they were rinsed in Tyrode buffer containing 10% saccharose
for 12 h then embedded into paraffin and cut into 3 µm thin sections. These sections were stained
with hematoxylin and eosin for routine morphological evaluation. Biotin-Streptavidin biochemical
method was used for immunohistochemistry (IMH) to detect: LL-37 (orb88370, working dilution 1:100,
Biorbyt Limited, Cambridge, UK); HBD-4 (ab14419, working dilution 1:200, Abcam, San Francisco,
California); HBD-2 (sc-20798, working dilution 1:100, Santa Cruz Biotechnology, Inc., Dallas,
Texas, United States); IL-1 (orb308737,working dilution 1:100, Biorbyt Limited, Cambridge, UK);
IL-10 (orb100193, working dilution 1:400, Biorbyt Limited, Cambridge, UK).
The stained slides were analyzed by light microscopy using nonparametric evaluation. The results
were evaluated by grading the appearance of the positively stained cells in the visual field [29].
The designation was as follows: 0, no positive structures in the visual field; 0/+, occasional positive
structures in the visual field; +, a few positive structures; +/++, a few to a moderate number of positive
structures in the visual field; ++, a moderate number of positive structures in the visual field; ++/+++,
moderate to numerous positive structures in the visual field; +++, numerous positive structures with
the visual field; +++/++++, numerous to abundant positive structures in the visual field; ++++,
abundant positive structures in the visual field.
For visual illustration, a Leica DM500RB digital camera and Microsoft Photo editor (version
19051.16210.0) were used.
2.3. Statistic Analysis
The statistical data processing was performed with IBM SPSS (Statistical Package for the Social
Sciences) version 25.0. We used the non-parametric Mann–Whitney U test to compare the control group
versus the patient group and Spearman’s rank correlation coefficient (ρ), where ρ = 0–0.3 was assumed
as a very weak correlation, ρ = 0.3–0.5 was assumed as a weak correlation, ρ = 0.5–0.7 was assumed as
a moderate correlation, ρ = 0.7–0.9 was assumed as a strong correlation, and ρ = 0.9–1 was assumed as
a very strong correlation. The significance level for all tests was selected as a p-value < 0.05 (5%).
3. Results
The rosacea-affected tissue material contained stratified squamosa epithelium and submucosal
connective tissue in all samples. Routine staining showed the presence of intraepithelial lymphocytes
and subepithelial inflammation with lymphocytes and macrophages, with signs of hyalinization in a
few of the cases (Figure 1).
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Figure 1. Routine stained micrographs of rosacea-affected facial skin tissues. (a) Note intraepithelial
lymphocytes in a 44-year-old female. Hematoxylin and eosin, X 200; (b) inflammation in the subepithelial
connective tissue in a 35-year-old female. Hematoxylin and eosin, X 200.
IL–1α was present in a moderate number of epithelial cells and in a few subepithelial connective
tissue cells of rosacea-affected samples. The IL-1αdistribution both in the epithelium and subepithelium
showed only occasional positive cells in the control group (Table 1, Figure 2a,b). In rosacea-affected
tissue, the number of IL-10-containing epitheliocytes greatly exceed the number of immunoreactive
cells in the epithelium of the control group (a few positive structures). Positive cells of IL-10 were more
observed in the connective tissue of the affected group (a few to moderate) than in the connective
tissue of the control group (few) (Table 1, Figure 2c,d). A moderate number of HBD-2 immunoreactive
positive structures appeared in the epithelium and subepithelium of the rosacea-affected group. A few
to a moderate number of HBD-2-containing structures were observed in the epithelium of the control
group, while no positive structures were detected in the connective tissues (Table 1, Figure 2e,f).
Table 1. Relative number of cytokines, defensins, and cathelicidin-positive structures in the
rosacea-affected facial epithelium and subepithelium.
Nr Age Diagnosis
IL-1α IL-10 HBD-2 HBD-4 LL-37
E CT E CT E CT E CT E CT
1 32 Papulopustular rosacea +++ +++ +++/++++ +++ +++ ++/+++ ++/+++ ++ +++ ++
2 35 Papulopustular rosacea ++/+++ ++/+++ +++/++++ ++/+++ ++ ++ +++ ++ ++/+++ ++/+++
3 36 Papulopustular rosacea +++ ++/+++ +++ +++ ++ +++ ++ +/++ +++ +++
4 36 Papulopustular rosacea ++ ++ +++ ++/+++ +/++ +++ +++ ++/+++ +/++ ++
5 44 Papulopustular rosacea ++/+++ ++ ++/+++ +++ ++ ++/+++ +++ ++/+++ +++ ++
6 4 Papulopustular rosacea /+++ + ++ ++/ + ++/+ ++/+++ ++ ++ + /+++
7 47 Papulopustular rosacea ++ 0/+ ++/+++ 0/+ ++ + ++ + ++ +/++
8 50 Papulopustular rosacea +/++ ++/+++ +++ ++/+++ +++ ++/+++ +++ ++ ++/+++ ++/+++
Subjects common ++ ++ +++ ++/+++ ++ ++ ++ ++ ++/+++ ++
Control common + 0/+ + + +/++ * 0/+ + 0 + +
Abbreviations: E, epithelium; CT, connective tissue; IL-1α, interleukin 1 alpha; IL-10, interleukin 10; HBD-2,
human beta defensin 2; HBD-4, human beta defensin 4; LL-37, cathelicidin; 0, no positive structures in the visual
field; 0/+, occasional positive structures in the visual field; +, few positive structures; +/++, few to moderate number
of positive structures in the visual field; ++, moderate number of positive structures in the visual field; ++/+++,
moderate to numerous positive structures in the visual field; +++, numerous positive structures with the visual field;
+++/++++, numerous to abundant positive structures in the visual field; ++++, abundant positive structures in the
visual field; *, statistically significant difference of the relative number in structures between the subjects and control.
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1α IMH, X 400; (b) occasional positive structures in epithelium and subepithelial connective tissue of 
control group in a 49-year-old male. IL-1α IMH, X 400; (c) moderate to numerous IL-10-containing 
epithelial cells and moderate immunoreactive cells in the connective tissue of a 44-year-old female. 
IL-10 IMH, X 250; (d) a few positive IL-10 structures in the epithelium and connective tissue of a 66-
year-old male. IL-10 IMH, X 200; (e) moderate number of HBD-2-marked immunoreactive positive 
structures appearing in the epithelium and few to moderate in the subepithelium of a 35-year-old 
female. HBD-2 IMH, X 400; (f) moderate HBD-2-positive cells in the epithelium and a few positive 
structures in the connective tissue of a 66-year-old male. HBD-2 IMH, X 400. 
Figure 2. Immunohistochemical micrographs in rosacea-affected tissues and in control samples.
(a) Moderate number of IL-1α-positive epitheliocytes and subepithelial cells in a 45-year-old female.
IL-1α IMH, X 400; (b) occasional positive structures in epithelium and subepithelial connective tissue
of control group in a 49-year-old male. IL-1α IMH, X 400; (c) moderate to numerous IL-10-containing
epithelial cells and moderate immunoreactive cells in the connective tissue of a 44-year-old female.
IL-10 IMH, X 250; (d) a few positive IL-10 structures in the epithelium and connective tissue of a
66-year-old male. IL-10 IMH, X 200; (e) moderate number of HBD-2-marked immunoreactive positive
structures appearing in the epithelium and few to moderate in the subepithelium of a 35-year-old
female. HBD-2 IMH, X 400; (f) moderate HBD-2-positive cells in the epithelium and a few positive
structures in the connective tissue of a 66-year-old male. HBD-2 IMH, X 400.
The HBD-4 distribution in the epithelium showed a moderate number of immunoreactive cells in
patient samples, while the control group showed only a few factor positive structures. Few HBD-4
marked structures were seen in the connective tissue of the affected group and no positive structures
in the connective tissue of the control group (Table 1, Figure 3).
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female. LL-37 IMH, X 250; (b) a few positive structures in the epithelium and connective tissue of the 
control group of a 66-year-old male. LL-37 IMH, X 200. 
A statistically significant difference between the marker distribution in the rosacea-affected 
tissue and the control group was noticed with HBD-2 in the epithelium (Table 2). 
Table 2. Mann–Whitney U test revealing statistically significant difference between rosacea-affected 
subjects and the control group. 
Detected Factors Mann-Whitney U Z-score p-Value 
HBD-2 in epithelium 6 −1.820 0.049 
Figure 3. Immunohistochemical micrographs in rosacea-affected tissues and in control samples. (a) Note
moderate HBD-4-containing epitheliocytes and in the subepithelial connective tissue of a 32-year-old
rosacea-affected male. HBD-4 IMH, X 250; (b) only a few HBD-4-positive structures were displayed in
the epithelium and no positive-stained structures in the connective tissue cells of 60-year-old control
subject. HBD-4 IMH, X 200.
Moderate to numerous cathelicidin-positive epithelial cells were detected in the patient samples.
In the epithelium and connective tissue of the control group and in the subepithelium of affected tissue,
a few positive structures of cathelicidin were detected (Table 1, Figure 4a,b).
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Figure 4. Immunohistochemical micrographs in rosacea-affected tissues and in control samples.
(a) Note the moderate LL-37-containing epithelial cells and only connective tissue cells in a 35-year-old
female. LL-37 IMH, X 250; (b) a few positive structures in the epithelium and connective tissue of the
control group of a 66-year-old male. LL-37 IMH, X 200.
A s atistically significant difference between the marker distribution in the rosacea-affected tissue
and the control group was noticed with HBD-2 in the epithelium (Table 2).
Table 2. Man –Whitney U test revealing statistically significant difference betw en rosacea-affected
subjects and the control group.
Detected Factors Mann-Whitney U Z-score p-Value
HBD-2 in epithelium 6 −1.820 0.049
Abbreviations: HBD-2, human beta defensin 2.
A correlation analysis of the rosacea-affected facial skin samples demonstrate a strong positive
correlation between HBD-4 in the connective tissue and HBD-4 in the epithelium. Furthermore, a strong
positive correlation was detected in the rosacea-affected tissue between IL-1 in the epithelium and
IL-10 in the connective tissue, IL-1 in the connective tissue, and IL-10 in the epithelium (Table 3).
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Table 3. Spearman’s rank correlation coefficient revealed correlations between the relative numbers of
different factors in rosacea-affected epithelium and subepithelial connective tissue.
Strength of Correlation Marker 1 Marker 2 Rho (ρ) p-Value
Strong positive correlation
HBD-4 in connective tissue HBD-4 in epithelium 0.828 0.011
IL-1α in epithelium IL-10 in connective tissue 0.771 0.025
IL-1α in connective tissue IL-10 in epithelium 0.721 0.044
Abbreviations: HBD-4, human beta defensin 4; HBD-2, human beta defensin 2; IL-1α, interleukin 1 alpha; IL-10,
interleukin 10.
4. Discussion
The long-term influence of trigger factors on the skin of the face, leading to dysfunction of the
pro- and anti- inflammatory system of the skin, is considered as the main cause of the pathogenesis of
rosacea [30]. The expression of IL-1, IL-10, HBD-2, and LL-37 proteins from all researched inflammatory
mediators was the highest. In our patients, it can be assumed that the increased release of dominant
mediators leads to damage of the facial tissue and the development of rosacea. This is proved by
the other scientists who have indicated the role of long-term trigger factors in the development of
abnormal immune system responses [31].
It is widely known that rosacea is characterized by inflammatory lesions of epidermal and
dermal tissues. IL-1 is a primary cytokine of inflammation which can be suppressed by IL-10. In the
present study, we found decreased levels of IL-1α and increased levels of IL-10 in lesion-affected
tissues, including normal immune system reaction on inflammation. It is confirmed by the strong
positive correlation of IL-1α and IL-10 in the epithelium and in the connective tissue. Other researches
confirm ability of IL-10 to inhibit IL-1α and what is more the two ways of inhibition are known:
(1) treatment with lipopolysaccharides (LPS), which increase IL-10 production; (2) autocrine IL-10
effects on signal transduction in the production of proIL-1 [32,33]. IL-10 inhibits Th1 and Th2 cytokine
production by suppressing the costimulatory molecule CD80 and CD86 expression in dendritic
cells and antigen-presenting cells [34]. Furthermore, IL-10 can decrease T-cell, B-cell, and mast cell
differentiation [35] and regulate the phase-specific migration of macrophages and secretion of cytokines
in damaged tissue. Interestingly, despite our results, a number of studies have demonstrated that IL-1
and other pro-inflammatory cytokine levels and activity were significantly elevated in rosacea-affected
skin [36]. As IL-1 is main mediator in cutaneous inflammation, it’s deregulation can cause the
development of inflammatory skin disease [7]. Additionally, in our research we can suggest that there
are no observable deregulation problems of the IL-1 and IL-10 system.
The HBD-2 level was quite similar in the subepithelium compared to IL-1 and IL-10. Usually,
the production of HBD-2 occurs in the uppermost layers of the epidermis. Relevant studies have
indicated HBD-2 expression in the epithelium of gastrointestinal and genitor-urinary tracts, and also in
the respiratory tract epithelium and in the secretory tubules of the submucosal glands [37]. Interestingly,
the expression of HBD-2 also can be induced in immune cells such as monocytes and macrophages by
cytokines and LPS [38], which can explain possible rosacea development in the subepithelium.
An interesting finding is the dominant secretion of HBD-2, but not of HBD-4, in the epithelium
of rosacea-affected tissue. HBD-2 plays one of the main roles in the development of epithelial
inflammation. It is the first human defensin (HBD-2) which is produced after adequate keratinocyte
stimulation by UBV; proinflammatory cytokines—for example, IL-1 and TNF-α; and Gram-negative
and Gram-positive bacteria and their products, such as bacterial endotoxins [39]. According to other
studies, IL-1-mediated stimulation significantly enhances the secretion of HBD-2 in keratinocytes of
an infected area [40], which shows HBD-2 as a protective factor during inflammation. Furthermore,
HBD-2 promotes the adaptive immune system by inducing the migration of CD45RO memory T
cells and shows chemoattractant activity due to binding to the CC chemokine receptor 6 (CCR6) on
neutrophils [41]; it also stimulates the migration of monocytes, macrophages, and dendritic cells. As a
result, HBD-2 intensifies the inflammatory process to reduce the damage caused by trigger factors.
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We detected an elevated level of LL-37 in the rosacea-affected epithelium, which indicates that it
is involved in the progression of inflammation. LL-37 normally is produced less in keratinocytes and
is converted to smaller peptides with enhanced antimicrobial function and a partial activity which is
strictly regulated [42,43]. However, it was found that, in patients with rosacea, the expression of LL-37
is higher and has a different structure [44,45]. UVB irradiation stimulates the increased excretion of
extracellular antimicrobial peptides (ATP), which cooperate with LL-37 to fully activate the P2 × 7R on
keratinocytes. As a result, LL-37 synergistical working with ATP enhances the secretion of IL-1 by
keratinocytes [46] and prolongs inflammation in rosacea-affected tissue.
5. Conclusions
Rosacea-affected facial skin is the main source of inflammatory cytokines. The increased level of
anti-inflammatory cytokine IL-10 and decreased level of pro-inflammatory cytokine IL-1 showed the
balance between the anti- and pro-inflammatory tissue responses.
The moderate number of HBD-2-positive structures in the connective tissue demonstrates a possible
intensification of local immunity increase in the case of rosacea in the subepithelium. The statistically
significant difference in the HBD-2 between the rosacea-affected subjects and the control group and
also moderate positive structures in the epithelium proves HBD-2′s important role in the common
local immune response of rosacea-affected tissue. The last effect seems to be intensified also by the
elevated level of LL-37 in the epithelium.
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